News
Sumitomo Heavy Industries Succeeds in Developing a Superconducting Cyclotron for Proton Therapy
Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (President: Shinji Shimomura, hereinafter referred to as "SHI") has conducted proton beam acceleration tests on its in-house developed superconducting
Sumitomo Heavy Industries, Ltd. Obtains Medical Device Approval for Manufacturing and Sales of Accelerator Based BNCT System and the Dose Calculation Program in Japan
Sumitomo Heavy Industries, Ltd. (TOKYO:6302)(President: Shinji Shimomura, referred as SHI hereinafter) has performed clinical trial of the BNCT*1) (Boron Neutron Capture Therapy) system using an
Nikkei und der Aufwertungsdruck des Yen!
Nikkei- Japanischer Yen steht weiterhin unter Aufwertungsdruck!
Nikkei- Yen und Biotech-Aktien drücken Index!
Nikkei 225: Nikkei profitiert vom schwachen Yen?
Nikkei – Japan probt den Ausbruch…
Mitsui Chemicals Group and ARRK Thailand to Organize the First MotionTech 2024 Exhibition
Mitsui Chemicals Asia Pacific (MCAP) – The Mitsui Chemicals Group and ARRK Thailand will jointly organize a public exhibition in Bangkok, Thailand, that showcases the various materials and
Mitsui Chemicals Develops Diffrar™ Optical Polymer Wafers for AR Glasses
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) has developed the Diffrar™ array of polymer wafers for waveguides used in augmented reality (AR) glasses, with a view to
Worried About U.S.-China Relations? Buy These 2 ETFs.
U.S.-China relations haven't been great in recent years, and the future is as uncertain as ever. The U.S. government is looking to reduce its reliance on China by helping to fund and encourage more
Shofu Dental Brasil, Super-Bond™ Dental Adhesive to Launch in Brazil
SHOFU INC. (Tokyo: 7979; President & COO: TAKAMI Tetsuo), SUN MEDICAL CO., LTD. (Head Office: Moriyama, Shiga; President & CEO: NAKAJIMA Yoshiyuki) and Mitsui Chemicals, Inc. (Tokyo: 4183
Innovation zur Resistenzbekämpfung: VECTRONTM T500, ein neues Produkt zur Vektorkontrolle, wurde von der Weltgesundheitsorganisation (WHO) präqualifiziert
VECTRONTM T500 ist ein neues IRS-Produkt, das TENEBENALTM enthält, den weltweit ersten Meta-Diamid-Wirkstoff (IRAC-Gruppe 30), der von Mitsui Chemicals Agro entwickelt wurde und sich in seiner
Innovation in Resistance Management: VECTRONTM T500, a New Vector Control Product, is Prequalified by the World Health Organization (WHO)
VECTRONTM T500 is a new IRS product containing TENEBENALTM, the world’s first meta-diamide active ingredient (IRAC Group 30) developed by Mitsui Chemicals Agro which has a different mode of action
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head
SHI receives first order for next-generation proton therapy system from Taichung Veterans General Hospital
Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (head office: Shinagawa City, Tokyo; President and CEO: Shinji Shimomura; hereinafter "SHI") has received an order from Taichung Veterans General
Mitsui Chemicals Group als Aussteller auf der K2022 Messe in Düsseldorf, Deutschlandy
Mitsui Chemicals, Inc. (Tokio: 4183; President & CEO: HASHIMOTO Osamu) und Mitsui Chemicals Europe GmbH (Düsseldorf, Deutschland; President: HIRAIWA Takeshi) sind als Mitsui Chemicals Group auf der
Mitsui Chemicals Group to Exhibit at K2022 Trade Fair in Düsseldorf, Germany
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) and Mitsui Chemicals Europe GmbH (Düsseldorf, Germany; President: HIRAIWA Takeshi) will exhibit at K2022 – the World’s No.1
Mitsui Chemicals showcases at FIND-DESIGN FAIR ASIA in Singapore new glass film, posica™ that improves view experience
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) announced today that it will be exhibiting at the FIND-DESIGN FAIR ASIA, which is set to be held at Marina Bay Sands
Mitsui Chemicals Catalysis Science Awards 2024
Mitsui Chemicals, Inc. (Tokio: 4183; Präsident und CEO: HASHIMOTO Osamu) gab heute bekannt, dass Online-Bewerbungen für die Mitsui Chemicals Catalysis Science Awards 2024 ab dem 1. September 2023
2024 Mitsui Chemicals Catalysis Science Awards
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) today announced that online applications for the 2024 Mitsui Chemicals Catalysis Science Awards will open on September 1
Internationale Forschungskooperation hat das Ziel, die Prävention und Behandlung von Herz-Kreislauf-Erkrankungen individueller zu gestalten
33 führende internationale Partner haben sich mit Unterstützung der Innovative Health Initiative (IHI) zum Forschungskonsortium iCARE4CVD zusammengeschlossen, um Herz-Kreislauf-Erkrankungen besser